Figure 1.
From Jack et al. (2012): Changes in AD biomarker data on the vertical axis vs. AD clinical stage, with preclinical staging highlighted in yellow Each biomarker is scaled from maximally normal (bottom) to maximally abnormal (top) with PET amyloid imaging (red line), biomarkers of neurodegeneration are FDG-PET or atrophy on MRI (blue line), and cognitive (purple line).